InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (2 ops.)
Insider track record
CFODisclosed buys
1
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by Riley Antony A, Chief Financial Officer. Insider active across 1 company, notably Forte Biosciences, Inc.. Aggregated, 17 filings have been recorded. Split: 1 buy · 2 sells. Total volume traded: €272k. History available since 7 September 2021. The latest transaction was disclosed on 1 July 2026 (Retenue fiscale). Regulator: SEC (Form 4). All data is openly available.
Declarations17 total
375 sharesCommon StockSEC:0001339375-26-000010:0
134 shares@ US$21.320.0006% mcap0.6% of flowCommon StockSEC:0001339375-26-000010:1
375 sharesCommon StockSEC:0001339375-26-000006:0
134 shares@ US$24.860.7% of flowCommon StockSEC:0001339375-26-000006:1
375 shares0Common StockSEC:0001415889-25-009697:0
375 shares0Common StockSEC:0001415889-25-000142:0
22,514 shares@ US$5.55229.0% of flowCommon StockSEC:0001415889-24-027557:0
Ideal exit: 18 Aug 2025 (T+270)
375 shares0Common StockSEC:0001415889-24-024495:0
9,375 shares0Common StockSEC:0001415889-24-019123:0
9,375 shares0Common StockSEC:0001415889-24-009859:0
9,375 shares0Common StockSEC:0001209191-24-000319:0
9,375 shares0Common StockSEC:0001209191-23-051480:0
148,514 shares@ US$1.0133.4% of flowCommon StockSEC:0001209191-23-044281:0
9,375 shares0Common StockSEC:0001209191-23-040968:0
9,375 shares0Common StockSEC:0001209191-23-023079:0
21,484 shares@ US$4.240.016% mcap50.0% of flowCommon StockSEC:0000899243-21-035246:0
21,484 shares@ US$4.2418.8% of flowCommon StockSEC:0000899243-21-035246
17 of 17 declarations
About Riley Antony A
Riley Antony A is the Chief Financial Officer at Forte Biosciences, Inc. In this role, he oversees the company's financial operations, including accounting, financial planning, and risk management. Antony is responsible for developing financial strategies that support the company's growth objectives. His expertise in finance is essential for ensuring the financial health of Forte Biosciences.
